与CA 15-3相比，一种黏蛋白样癌相关抗原在监测乳腺癌患者中的临床价值。

Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.

作者信息

Miserez A R, Günes I, Müller-Brand J, Walther E, Fridrich R, Mäcke H

机构信息

Institute of Nuclear Medicine, University Hospital, Basel, Switzerland.

出版信息

Eur J Cancer. 1991;27(2):126-31. doi: 10.1016/0277-5379(91)90468-s.

DOI:10.1016/0277-5379(91)90468-s

PMID:1827273

Abstract

A new tumour marker, mucin-like carcinoma-associated antigen (MCA), was evaluated in 176 breast cancer patients classified either as free of tumour (NED, n = 141) or as having metastases (PD, n = 35). During the 5 year follow-up, 842 measurements of MCA and 363 measurements of CA 15-3 were done. MCA levels were significantly increased in the PD group (P = 0.0001) but not in the NED group. The sensitivities of the MCA and the CA 15-3 assays were 84% and 78% and the specificities were 81% and 78%, respectively. The negative predictive value of 97% for MCA was significantly higher (P = 0.0001) than the 88% for CA 15-3. Thus the MCA enzyme immunoassay is at least equivalent to the CA 15-3 test and is recommended in the assessment of metastatic spread or tumour recurrence in breast cancer patients.

摘要

一种新的肿瘤标志物——黏蛋白样癌相关抗原（MCA），在176例乳腺癌患者中进行了评估，这些患者分为无肿瘤（NED，n = 141）或有转移（PD，n = 35）两类。在5年随访期间，进行了842次MCA测量和363次CA 15 - 3测量。PD组MCA水平显著升高（P = 0.0001），而NED组未升高。MCA和CA 15 - 3检测的敏感性分别为84%和78%，特异性分别为81%和78%。MCA的阴性预测值为97%，显著高于CA 15 - 3的88%（P = 0.0001）。因此，MCA酶免疫测定至少与CA 15 - 3检测相当，推荐用于评估乳腺癌患者的转移扩散或肿瘤复发。